Monogram Technologies INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Monogram Technologies Inc. announced a definitive merger agreement with Zimmer Biomet Holdings, Inc., offering shareholders $4.04 cash plus contingent value rights per common share.
NASDAQ
Monogram Technologies Inc. announces its Q1 2025 financial results, including a net loss of $3.2 million, while also celebrating FDA 510(k) clearance for its mBs TKA System and regulatory approval for a clinical trial in India.
NASDAQ
10-Q: Monogram Technologies Reports Q3 2024 Results, Provides Update on FDA Filing and Capital Raises
Monogram Technologies reported a net loss of $5.03 million for the third quarter of 2024, while also providing updates on their FDA 510(k) submission and recent capital raising activities.
NASDAQ
Monogram Technologies reported a net loss for the second quarter of 2024, while also making progress on its robotic surgery system and securing additional funding.
NASDAQ
Monogram Orthopaedics reported a net loss of $3.5 million for Q1 2024, while making progress on its robotic surgical system and preparing for a 510(k) submission.